Search results
Results from the WOW.Com Content Network
Lung cancer is the most diagnosed and deadliest cancer worldwide, with 2.2 million cases in 2020 resulting in 1.8 million deaths. [3] Lung cancer is rare in those younger than 40; the average age at diagnosis is 70 years, and the average age at death 72. [2] Incidence and outcomes vary widely across the world, depending on patterns of tobacco use.
Small-cell lung carcinoma (SCLC) has long been divided into two clinicopathological stages, termed limited stage (LS) and extensive stage (ES). [8] The stage is generally determined by the presence or absence of metastases, whether or not the tumor appears limited to the thorax, and whether or not the entire tumor burden within the chest can feasibly be encompassed within a single radiotherapy ...
Lung cancer staging is the assessment of the extent to which a lung cancer has spread from its original source. As with most cancers, staging is an important determinant of treatment and prognosis. In general, more advanced stages of cancer are less amenable to treatment and have a worse prognosis.
The Pancoast tumor was first described by Hare in 1838 as a "tumor involving certain nerves". [2] It was not until 1924 that the tumor was described in further detail, when Henry Pancoast, a radiologist from Philadelphia, published an article in which he reported and studied many cases of apical chest tumors that all shared the same radiographic findings and associated clinical symptoms, such ...
Continued cigarette smoking negatively impacts limited-stage small cell lung cancer survival. All clinicians and care providers should strongly encourage smoking cessation at the diagnosis of limited stage small cell lung cancer. Comparing to continued smokers, patients who quit at or after diagnosis lower the risk of death by 45%. [28]
Many small series have suggested that the prognosis of lung tumors with giant cells is worse than that of most other forms of non-small-cell lung cancer (NSCLC), [11] including squamous cell carcinoma, [42] and spindle cell carcinoma. [42] The overall five-year survival rate in GCCL varies between studies but is generally considered to be very low.
LEMS is often associated with lung cancer (50–70%), specifically small-cell carcinoma, [4] making LEMS a paraneoplastic syndrome. [5] Of the people with small-cell lung cancer, 1–3% have LEMS. [3] In most of these cases, LEMS is the first symptom of the lung cancer, and it is otherwise asymptomatic. [3]
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. [1] [2] [3] As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma.